アブストラクト
| Title | (3) 悪性脳腫瘍 |
|---|---|
| Subtitle | Top Feature 脳神経外科 専門医への道 : その先を見据えて 領域別解説 |
| Authors | 白畑充章 |
| Authors (kana) | |
| Organization | 埼玉医科大学国際医療センター脳脊髄腫瘍科 |
| Journal | 脳神経外科速報 |
| Volume | 31 |
| Number | 3 |
| Page | 387-392 |
| Year/Month | 2021 / |
| Article | 報告 |
| Publisher | メディカ出版 |
| Abstract | 「I. はじめに」 本稿を読まれる専門医試験受験を控えた先生方はすでに過去問などで試験勉強を進められていることと思う. 本稿前半はふだん悪性脳腫瘍の診療に携わる機会の少ない先生にとっても悪性脳腫瘍領域の試験対策を効率的に行えるように, という観点で記述した. また後半は専門医試験の後に悪性脳腫瘍領域をsubspecialityとすることを考えている先生方に向けて記述した. いずれも一助になれば幸いである. 「II. 専門医試験対策」 悪性脳腫瘍の専門医試験対策としては, 膠芽腫, グリオーマ, 中枢神経系原発悪性リンパ腫(PCNSL), 転移性脳腫瘍, その他の項目に分けて整理し, 重複する部分もあるがさらに試験で問われやすい遺伝子異常関連の問題についてポイントを整理するとよい. 臨床試験の結果は治療方針に直結するエビデンスとなることから試験で問われやすいが, 成人膠芽腫, 成人転移性脳腫瘍, PCNSLの治療方針に関しては, 脳腫瘍学会より『脳腫瘍診療ガイドライン』が作成されており, 重要な臨床試験の結果がまとめられているので, これに沿って学習するのが手っ取り早い. |
| Practice | 臨床医学：外科系 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に1,749円(税込) です。
参考文献
- 2) National Comprehensive Cancer Network: NCCN Guidelines(2021年3月31日最終閲覧), https://www.nccn.org/professionals/physician_gls/default.aspx
- 3) Weller M, et al: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18: 170-86, 2021
- 4) Kocher M, et al: Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29: 134-41, 2011
- 5) Soffietti R, et al: A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol 31: 65-72, 2013
- 6) Brown PD, et al: Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA 316: 401-9, 2016
残りの20件を表示する
- 7) Li J, et al: The Diminishing Role of Whole-Brain Radiation Therapy in the Treatment of Brain Metastases. JAMA Oncol 3: 1023-4, 2017
- 8) Stupp R, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-96, 2005
- 9) Chinot OL, et al: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370: 709-22, 2014
- 10) Gilbert MR, et al: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370: 699-708, 2014
- 11) Stupp R, et al: Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA 318: 2306-16, 2017
- 12) Roa W, et al: Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22: 1583-8, 2004
- 13) Keime-Guibert F, et al: Radiotherapy for glioblastoma in the elderly. N Engl J Med 356: 1527-35, 2007
- 14) Wick W, et al: Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13: 707-15, 2012
- 15) Perry JR, et al: Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med 376: 1027-37, 2017
- 16) Morris PG, et al: Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol 31: 3971-9, 2013
- 17) Narita Y, et al: Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro Oncol 23: 122-33, 2021
- 18) Brown PD, et al: Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol 38: 1019-29, 2020
- 19) Brown PD, et al: Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 15: 1429-37, 2013
- 20) Colclough N, et al: Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs. Clin Cancer Res 27: 189-201, 2021
- 21) Reungwetwattana T, et al: CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol: JCO2018783118, 2018
- 22) Yang JCH, et al: Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. J Clin Oncol 38: 538-47, 2020
- 23) Stichel D, et al: Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol 136: 793-803, 2018
- 24) Shirahata M, et al: Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol 136: 153-66, 2018
- 25) International Agency for Research on Cancer: 408p(Louis DN, et al: WHO Classification of Tumours of the Central Nervous System. World Health Organization, Geneve, 2016)
- 26) Ahn JH, et al: Risk for leptomeningeal seeding after resection for brain metastases: implication of tumor location with mode of resection. J Neurosurg 116: 984-93, 2012
